Literature DB >> 3132653

The monoclonal antibody, Alz 50, recognizes tau proteins in Alzheimer's disease brain.

N Nukina1, K S Kosik, D J Selkoe.   

Abstract

The monoclonal antibody, Alz 50, is known to label many dystrophic neurites and neurofibrillary tangles in Alzheimer's disease (AD) brain. Using immunoprecipitation and immunoblotting, we have compared Alz 50 to monoclonal antibodies directed at two known components of neurofibrillary tangles, tau and ubiquitin, in order to characterize further the antigens recognized by Alz 50 in AD brain. Alz 50 labeled purified tau proteins in a highly similar fashion to two well-characterized tau monoclonal antibodies. Alz 50 precipitated proteins at the molecular weight of 50-70 kDa from AD but not normal brain; these proteins were reactive with the tau antibodies. In addition, Alz 50 precipitated proteins migrating principally around 160-180 kDa from AD but not normal brain; the relationship of the latter proteins to tau remains unclear. None of these proteins reacted with a ubiquitin antibody. We hypothesize that the proteins recognized by Alz 50 at much higher levers in AD than normal brain include modified and aggregated forms of tau.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132653     DOI: 10.1016/0304-3940(88)90455-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  Massive accumulation of modified tau and severe depletion of normal tau characterize the cerebral cortex and white matter of Alzheimer's disease. Demonstration using the hydrated autoclaving method.

Authors:  R W Shin; T Iwaki; T Kitamoto; Y Sato; J Tateishi
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

Review 2.  Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

3.  Pathological proteins Tau 64 and 69 are specifically expressed in the somatodendritic domain of the degenerating cortical neurons during Alzheimer's disease. Demonstration with a panel of antibodies against Tau proteins.

Authors:  A Delacourte; S Flament; E M Dibe; P Hublau; B Sablonnière; B Hémon; V Shérrer; A Défossez
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

4.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

Authors:  S G Greenberg; P Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 5.  Alzheimer's disease--neuropathological aspects.

Authors:  C Bergeron
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

6.  Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.

Authors:  E B Mukaetova-Ladinska; C R Harrington; M Roth; C M Wischik
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

7.  Brain transplants of cells expressing the carboxyl-terminal fragment of the Alzheimer amyloid protein precursor cause specific neuropathology in vivo.

Authors:  R L Neve; A Kammesheidt; C F Hohmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

8.  Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.

Authors:  V Askanas; W K Engel; M Bilak; R B Alvarez; D J Selkoe
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

9.  Immunohistological study on brains of Alzheimer's disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5.

Authors:  H Takahashi; K Hirokawa; S Ando; K Obata
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Immunohistochemical and histopathologic correlates of Alzheimer's disease-associated Alz-50 immunoreactivity quantified in homogenates of cerebral tissue.

Authors:  S M de la Monte; R A Spratt; J Chong; H A Ghanbari; J R Wands
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.